SCHEMBL6748419

SCHEMBL6748419

CCc1cccc(NC(=O)NC(c2ccc(C(=O)NCCC(=O)O)cc2)c2ccc(C3=CCCCC3)cc2)c1S(=O)(=O)Nc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 12/20 0.42
GIPR P48546 8/20 0.42
GLP1R P43220 1/20 0.42
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
POLB P06746 1/20 0.40
ADCY6 O43306 2/20 0.38
ADCY3 O60266 2/20 0.38
ADCY9 O60503 2/20 0.38
ADCY5 O95622 2/20 0.38
ADCY8 P40145 2/20 0.38
ADCY7 P51828 2/20 0.38
ADCY2 Q08462 2/20 0.38
ADCY1 Q08828 2/20 0.38
ADCY4 Q8NFM4 2/20 0.38
NPSR1 Q6W5P4 3/20 0.38
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6751677 0.92 ALDH1A1 (0.43) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL2652194 0.90 GCGR (0.41) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL2651588 0.90 OPRM1 (0.39) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL2651923 0.89 GCGR (0.42) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL6748418 0.87 GCGR (0.48) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL2650819 0.86 OPRM1 (0.40) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL6751674 0.85 SMN1; SMN2 (0.50) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL2650884 0.84 OPRM1 (0.42) GCGRALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL2651922 0.82 NPSR1 (0.50) GCGRGIPRGLP1RALDH1A1MAPT
SCHEMBL2652191 0.82 GCGR (0.47) GCGRGIPRGLP1RALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127560-A1 Glucagon antagonists/inverse agonists MADSEN PETER (DK) 2004-07-01 US claimed
US-6706744-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2004-03-16 US claimed
US-20030065031-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-04-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127560-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885
US-20030065031-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.